Table 2.

Summary of tumor responses in patients who received lenvatinib or placebo.

Parameter	Lenvatinib (n = 103)	Placebo (n = 48)
Best overall response, n (%)
Complete response	2 (1.9)	0
Partial response	70 (68.0)	0
Stable disease	21 (20.4)	27 (56.3)
Durable stable diseasea	12 (11.7)	22 (45.8)
Progressive disease	6 (5.8)	16 (33.3)
Not evaluable/unknown	4 (3.9)	5 (10.4)
Objective response rate, n (%)	72 (69.9)	0
Difference, % (95% CI)	69.9 (61.0–78.8)
P value	< 0.0001
Disease control rateb, n (%)	93 (90.3)	27 (56.3)
Difference, % (95% CI)	34.0 (18.9–49.2)
Clinical benefit ratec, n (%)	84 (81.6)	22 (45.8)
Difference, % (95% CI)	35.7 (19.8–51.7)

Abbreviation: CI, confidence interval.

^aDurable stable disease = duration of ≥ 23 weeks.

^bDisease control rate = complete response, partial response, and stable disease.

^cClinical benefit rate = complete response, partial response, and durable stable disease.